(Q37539440)

English

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

scientific article published on July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). (English)

1 reference

Europe PubMed Central

20 August 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Alejandro Vázquez-Martín

1

1 reference

Europe PubMed Central

20 August 2017

Cristina Oliveras-Ferraros

2

1 reference

Europe PubMed Central

20 August 2017

Sonia del Barco

3

1 reference

Europe PubMed Central

20 August 2017

Begoña Martín-Castillo

4

1 reference

Europe PubMed Central

20 August 2017

Javier A Menéndez

5

1 reference

Europe PubMed Central

20 August 2017

publication date

1 July 2009

1 reference

Europe PubMed Central

20 August 2017

Clinical and Translational Oncology

1 reference

Europe PubMed Central

20 August 2017

11

1 reference

Europe PubMed Central

20 August 2017

7

1 reference

Europe PubMed Central

20 August 2017

455-459

1 reference

Europe PubMed Central

20 August 2017

https://scigraph.springernature.com/pub.10.1007/s12094-009-0384-0

0 references

Activation of AMPK is necessary for killing cancer cells and sparing cardiac cells

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0384-0

21 January 2018

Genome-wide inhibitory impact of the AMPK activator metformin on [kinesins, tubulins, histones, auroras and polo-like kinases] M-phase cell cycle genes in human breast cancer cells.

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0384-0

21 January 2018

Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0384-0

21 January 2018

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

1 reference

https://api.crossref.org/works/10.1007%2FS12094-009-0384-0

21 January 2018

Insulin-lowering effects of metformin in women with early breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin induces unique biological and molecular responses in triple negative breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Doctors seek to prevent breast cancer recurrence by lowering insulin levels.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is it time to test metformin in breast cancer clinical trials?

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Implication of AMP-activated protein kinase and Akt-regulated survivin in lung cancer chemopreventive activities of deguelin

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-2/neu transgenic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin decelerates aging and development of mammary tumors in HER-2/neu transgenic mice

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin, insulin, breast cancer and more...

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration

1 reference

https://pubmed.ncbi.nlm.nih.gov/19574203

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S12094-009-0384-0

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37539440&oldid=1521595647"